Home › Research › Biomarkers
Ultrasensitive SERS nanoprobe-based multiplexed digital sensing platform for the simultaneous quantification of Alzheimer's disease biomarkers
Shim JE, Kim YJ, Hahm E, Choe JH, Baek A, Kim RM, You EA.. Biosensors & bioelectronics, 2025-01-28
Topic: Amyloid, tau and blood-test diagnosis
Alzheimer's disease (AD) is a severe neurodegenerative disease that requires early diagnosis to manage its progression. Although the simultaneous detection of multiple AD biomarkers is expected to facilitate early assessment of AD risk, the lack of multiplexed sensing platforms for accurately quantifying multiple AD biomarkers remains a challenge. Here, we present a multiplexed digital sensing platform based on bumpy core-shell (BCS) surface-enhanced Raman spectroscopy (SERS) nanoprobes for ultrasensitive, quantitative, and simultaneous detection of Aβ42 and Aβ40 as AD biomarkers, enabling the accurate determination of the Aβ42/Aβ40 ratio. We synthesized BCS SERS nanoprobes with distinct Raman reporters to generate unique, intense, and reproducible SERS signals, offering single-nanoparticle sensitivity and quantification capabilities. These nanoprobes were subsequently employed in SERS-based immunoassays combined with digital SERS analysis for multiplexed quantification. The proposed platform accurately and quantitatively detected Aβ42 and Aβ40 across a range of five orders of magnitude, with a limit of detection of 8.7× 10 -17 g/mL (1.9 × 10 -17 M) for Aβ42 and 1.0 × 10 -15 g/mL (2.3 × 10 -16 M) for Aβ40, surpassing the performance of conventional enzyme-linked immunosorbent assays. Based on the exclusive detection of Aβ42 and Aβ40 using distinct SERS nanoprobes, the proposed sensing platform can also accurately quantify Aβ42 and Aβ40 at clinically relevant levels in both cerebrospinal fluid and blood plasma. Therefore, this sensing platform can be used to accurately and reliably determine the Aβ42/Aβ40 ratio, thus serving as an effective tool for the early diagnosis of AD.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Shim, J. E., Kim, Y. J., Hahm, E., Choe, J. H., Baek, A., Kim, R. M., et al. (2025). Ultrasensitive SERS nanoprobe-based multiplexed digital sensing platform for the simultaneous quantification of Alzheimer's disease biomarkers. Biosensors & bioelectronics. https://doi.org/10.1016/j.bios.2025.117216
Vancouver
Shim JE, Kim YJ, Hahm E, Choe JH, Baek A, Kim RM, et al. Ultrasensitive SERS nanoprobe-based multiplexed digital sensing platform for the simultaneous quantification of Alzheimer's disease biomarkers. Biosensors & bioelectronics. 2025. doi:10.1016/j.bios.2025.117216. PMID: 39899917.
BibTeX
@article{shim2025-39899917,
author = {Shim, J. E. and Kim, Y. J. and Hahm, E. and Choe, J. H. and Baek, A. and Kim, R. M. and You, E. A.},
title = {{Ultrasensitive SERS nanoprobe-based multiplexed digital sensing platform for the simultaneous quantification of Alzheimer's disease biomarkers}},
journal = {Biosensors \& bioelectronics},
year = {2025},
doi = {10.1016/j.bios.2025.117216},
pmid = {39899917},
url = {https://doi.org/10.1016/j.bios.2025.117216}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- We synthesized BCS SERS nanoprobes with distinct Raman reporters to generate unique, intense, and reproducible SERS signals, offering single-nanoparticle sensitivity and quantification capabilities.
- These nanoprobes were subsequently employed in SERS-based immunoassays combined with digital SERS analysis for multiplexed quantification.
- The proposed platform accurately and quantitatively detected Aβ42 and Aβ40 across a range of five orders of magnitude, with a limit of detection of 8.7× 10 -17 g/mL (1.9 × 10 -17 M) for Aβ42 and 1.0 × 10 -15 g/mL (2.3 × 10 -16 M) for Aβ40, surpassing the performance of conventional enzyme-linked immunosorbent assays.
- Based on the exclusive detection of Aβ42 and Aβ40 using distinct SERS nanoprobes, the proposed sensing platform can also accurately quantify Aβ42 and Aβ40 at clinically relevant levels in both cerebrospinal fluid and blood plasma.
- Therefore, this sensing platform can be used to accurately and reliably determine the Aβ42/Aβ40 ratio, thus serving as an effective tool for the early diagnosis of AD.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Evidence strengthLow
How this study scored 41/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multi-centre collaboration, so those were left out: it earned 24 of the 58 points we could judge it on, which is 41 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Biosensors & bioelectronics) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 39899917) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 24 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 24 of the 58 points we could judge it on is 41 out of 100. |
| Total | 41 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related studies in Biomarkers
Also tagged “ultrasensitive”
2 studies in the library carry the topic tag “ultrasensitive”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 2 tagged studies.